Choosing the right biologic for complications of inflammatory bowel disease.
Crohn’s disease
Inflammatory bowel disease
anti-TNF therapy
biologic therapy
extra-intestinal manifestations
tofacitinib
ulcerative colitis
ustekinumab
vedolizumab
Journal
Expert review of gastroenterology & hepatology
ISSN: 1747-4132
Titre abrégé: Expert Rev Gastroenterol Hepatol
Pays: England
ID NLM: 101278199
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
pubmed:
1
2
2022
medline:
18
3
2022
entrez:
31
1
2022
Statut:
ppublish
Résumé
Inflammatory bowel disease (IBD) is a chronic, inflammatory condition that involves the intestinal tract, and can also present with extra-intestinal manifestations (EIM). Choosing the right treatment for IBD is often nuanced and decisions can become even more complicated when a patient presents with or develops a complication of the disease. We aimed to provide an overview of the most common complications of IBD, specifically intestinal and EIM, and summarize the data regarding biologic therapy for treatment of these conditions. A comprehensive literature review was performed using PubMed and Medline databases to identify studies published in the English language relevant to the broad scope of this review. There are still significant gaps in our understanding of the pathophysiology of IBD and its treatment, especially in regards to complications of the disease. As novel therapies continue to emerge for treatment of IBD, we feel concurrent examination of their impact on intestinal complications and EIM of IBD is important and should be a priority of future research.
Identifiants
pubmed: 35094628
doi: 10.1080/17474124.2022.2036122
doi:
Substances chimiques
Biological Products
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM